Carasent (Q2 Initial take): Solid Q2 in line with expectations - Redeye
Redeye comments on Carasent’s Q2 2026 report, showing solid organic ARR growth and continued scalability. We remain positive and will likely make minor changes to our forecasts and our SEK34 Base Case.
ANNONS
Redeye comments on Carasent’s Q2 2026 report, showing solid organic ARR growth and continued scalability. We remain positive and will likely make minor changes to our forecasts and our SEK34 Base Case.
